VIA
IRWD icon

Vident Investment Advisory’s Ironwood Pharmaceuticals IRWD Stock Holding History

Vident Investment Advisory’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,696
Closed -$135K – 516
2023
Q2 		$135K Buy
+12,696
New +$136K ﹤0.01% 1107
2022
Q4 		– Sell
-122,204
Closed -$1.27M – 1257
2022
Q3 		$1.27M Buy
+122,204
New +$1.39M 0.04% 507

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vident Investment Advisory's IRWD Position: Q3 2023 in Review

Vident Investment Advisory sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2023, closing a stake of 12,696 shares — an estimated $135K sold.

Vident Investment Advisory first reported a position in IRWD in Q3 2022 and held it in 2 quarters. The position peaked at $1.27M in Q3 2022. 248 funds tracked by Wall St. Rank hold IRWD as of Q3 2023.

  • Vident Investment Advisory reported no remaining Ironwood Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 12,696 Ironwood Pharmaceuticals shares in Q3 2023, an estimated $135K.
  • Vident Investment Advisory first reported a position in Ironwood Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Vident Investment Advisory's Ironwood Pharmaceuticals position peaked at $1.27M in Q3 2022.
  • 248 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.